News & Updates

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022
NAFLD tied to CVD risk even in lean patients
NAFLD tied to CVD risk even in lean patients
06 Jun 2022 byElvira Manzano

Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.

NAFLD tied to CVD risk even in lean patients
06 Jun 2022
Losing weight may help control cardiovascular risk in T2D
Losing weight may help control cardiovascular risk in T2D
04 Jun 2022
Severe hypoglycaemia linked to tighter glucose control, higher worry scores
Severe hypoglycaemia linked to tighter glucose control, higher worry scores
03 Jun 2022

Among older Southeast Asian type 2 diabetes mellitus patients, severe hypoglycaemia tends to occur with tighter glycaemic control, greater impaired hypoglycaemia awareness, and higher worry scores, regardless of treatment regimens, according to a study.

Severe hypoglycaemia linked to tighter glucose control, higher worry scores
03 Jun 2022